

ARTICLE **OPEN**

Application of *QPLEX*TM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition

Dongjoon Lee^{1,2,11}, Jong-Chan Park^{1,2,3,4,11}, Keum Sim Jung⁵, Jiyeong Kim⁵, Ji Sung Jang⁵, Sunghoon Kwon⁵, Min Soo Byun⁶, Dahyun Yi⁷, Gihwan Byeon⁷, Gijung Jung⁷, Yu Kyeong Kim⁸, Dong Young Lee^{7,9,10}, Sun-Ho Han^{1,2,3} and Inhee Mook-Jung^{1,2,3}

© The Author(s) 2022

The deposition of beta-amyloid (A β) in the brain precedes the onset of symptoms such as cognitive impairment in Alzheimer's disease (AD); therefore, the early detection of A β accumulation is crucial. We previously reported the applicability of the *QPLEX*TM Alz plus assay kit for the prescreening of A β accumulation. Here, we tested the specific application of the kit in a large cohort of cognitively normal (CN) individuals of varying ages for the early detection of A β accumulation. We included a total of 221 CN participants with or without brain A β . The *QPLEX*TM biomarkers were characterized based on age groups (1st–3rd tertile) and across various brain regions with cerebral amyloid deposition. The 3rd tertile group (>65 years) was found to be the most suitable age group for the application of our assay kit. Receiver operating characteristic curve analysis showed that the area under the curve (AUC, discrimination power) was 0.878 with 69.7% sensitivity and 98.4% specificity in the 3rd tertile group. Additionally, specific correlations between biomarkers and cerebral amyloid deposition in four different brain regions revealed an overall correlation with general amyloid deposition, consistent with previous findings. Furthermore, the combinational panel with plasma A β 1–42 levels maximized the discrimination efficiency and achieved an AUC of 0.921 with 95.7% sensitivity and 67.3% specificity. Thus, we suggest that the *QPLEX*TM Alz plus assay is useful for prescreening brain A β levels in CN individuals, especially those aged >65 years, to prevent disease progression via the early detection of disease initiation.

Experimental & Molecular Medicine (2022) 54:61–71; <https://doi.org/10.1038/s12276-021-00719-3>

INTRODUCTION

Alzheimer's disease (AD) is the most prevalent form of the disease that causes dementia, affecting more than 40 million individuals worldwide¹. There are various causes of Alzheimer's disease^{2–4}, and the primary pathology of AD comprises severe amyloid deposition and neurofibrillary tangles in the brain⁵. Multiple methods for assessing brain amyloid levels have been developed in recent years, including the use of Pittsburgh compound B positron emission tomography (PiB-PET)⁶. However, due to the limited accessibility of PiB-PET, ongoing trials are being conducted to find surrogates for PiB-PET, such as blood biomarkers that reliably indicate brain amyloid levels⁷. Without the need for burdensome cerebrospinal fluid extraction or high-cost brain imaging, blood-based diagnoses have numerous advantages that have drawn the attention of researchers, clinicians, and the elderly population.

Several studies have reported changes in blood biomarker levels during the onset and progression of AD^{8–10}. Moreover, the

fact that brain amyloid deposition precedes cognitive abnormalities emphasizes the need for screening in cognitively normal (CN) individuals⁹. During the preclinical or presymptomatic stage of AD, PiB-PET-positive individuals, regardless of their cognitive state, are at a risk of developing significant cognitive impairment; this period is considered the optimal treatment period¹¹. Considering this, the prediction of AD progression based on blood biomarkers could be beneficial to CN individuals prone to progression toward mild cognitive impairment (MCI) by providing preventive measures and aiding in early intervention.

In our previous studies, we identified a novel blood-based biomarker panel (beta-amyloid 1–40, A β 1–40; angiotensin-converting enzyme, ACE; periostin, POSTN; and galectin-3 binding protein, LGALS3BP) to predict cerebral amyloid deposition^{11,12}. Evidence for the relevance of A β 1–40 and ACE to AD has been reported previously^{13–16}. A β 1–40 is one of the most canonical forms of an AD blood biomarker¹³. ACE is known to directly

¹Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. ²SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. ³Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. ⁴Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London WC1E 6BT, UK. ⁵QuantaMatrix Inc, Seoul 03080, Republic of Korea. ⁶Department of Psychiatry, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea. ⁷Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea. ⁸Department of Nuclear Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Republic of Korea. ⁹Department of Psychiatry, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea. ¹⁰Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul 03080, Republic of Korea. ¹¹These authors contributed equally: Dongjoon Lee, Jong-Chan Park. ✉email: selfpsy@snu.ac.kr; sunho@snu.ac.kr; inhee@snu.ac.kr

degrade beta-amyloid protein¹⁴, retard beta-amyloid aggregation¹⁵, and convert A β 1–42 to A β 1–40¹⁶. In the case of POSTN and LGALS3BP, their roles in the immune response suggest possible relevance to AD pathology. POSTN can recruit eosinophils¹⁷; LGALS3BP is known to be upregulated in activated microglia¹⁸ and plays a role in inflammation in the periphery through inhibition of neutrophil activation upon binding of its ligand Gal-3¹⁹ and modulation of natural killer cell activity and interleukin production²⁰.

We developed a prescreening platform for PiB-PET positivity using this *QPLEX*TM panel for individuals >55 years old, including CN individuals and patients with MCI and dementia²¹. Here, we investigated the application of the *QPLEX*TM Alz plus assay kit to CN individuals for the early diagnosis of AD and aimed to demonstrate the applicability of this kit in distinguishing between CN individuals with and without amyloid burden, especially in restricted age groups (the 3rd tertile group, >65 years), for an efficient diagnosis. The additional use of plasma beta-amyloid (A β) 1–42 with respect to the biomarkers currently in the kit was expected to improve diagnostic performance. Thus, we aimed to investigate whether the *QPLEX*TM Alz plus assay kit is a useful method for detecting and prescreening cerebral amyloid deposition in preclinical AD.

MATERIALS AND METHODS

Participants

A total of 221 CN individuals were included in this cross-sectional study. All participants were recruited as part of the Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease (KBASE) and underwent appropriate clinical and neuropsychological assessments in accordance with the KBASE assessment protocol. The recruitment of participants, clinical diagnostic criteria for AD, and further information are detailed in our previous reports involving the same KBASE cohort^{11,21,22}.

PiB-PET

All participants underwent PiB-PET scans using a 3.0-Tesla PET-magnetic resonance (MR) scanner (Siemens Healthineers, Erlangen, Germany). Each participant was intravenously injected with 555 MBq of [11 C] PiB (450–610 MBq) PET tracer, which enabled the visualization of cerebral amyloid deposition. The automatic anatomic algorithm determined the degree of amyloid accumulation, which was calculated using the standardized uptake value ratio (SUVR). Four regions of interest (ROIs) in the brain were chosen within the following regions: the lateral temporal (LT), lateral parietal (LP), posterior cingulate-precuneus (PC-PRC), and frontal (FR) regions. These regions were identified by an automatic anatomic algorithm and a region-combinative method, as reported previously²³. We determined the negative and positive cutoff values for PiB-PET based on the Mayo Clinic Alzheimer's Disease Research Center and Mayo Clinic Study of Aging criteria using the same approach as that described previously^{24–28}. If the SUVR value was ≥ 1.4 for at least one of the four ROIs, the individual was defined as PiB-positive (PiB⁺). Additional information on the imaging protocols was provided in our previous study^{12,22}.

Blood sampling

All fasting blood samples were collected at 9:00 am. Whole blood samples were collected in K2 EDTA tubes (BD Vacutainer Systems, Plymouth, UK) and centrifuged at 700 \times g for 5 min at room temperature (RT). The supernatant was collected and centrifuged, and the tubes were stored at -80°C .

xMAP technology for the quantification of plasma A β 1–42 and A β 1–40

To quantify the concentrations of plasma A β 1–42 and A β 1–40, we performed a Bioplex 200 assay (Bio-Rad, Hercules, CA, USA) using xMAP technology and an INNO-BIA plasma A β forms kit (Fujirebio Diagnostics, Gothenburg, Sweden) in accordance with the manufacturer's guidelines¹². Briefly, plasma samples were diluted 3-fold in plasma diluent buffer. After washing the plate to initialize the filter, the diluted beads were added to

the wells of the plates and transferred to the filters. Next, the conjugated beads, standards, samples, and controls were added and incubated overnight. The next day, each well was washed and incubated with the detection solution for 1 h. After incubation, further washing steps were performed, and the reading solution was added. Finally, the levels of plasma A β 1–42 and A β 1–40 were quantified using the Bioplex 200 system.

*QPLEX*TM Alz plus assay

All quantification methods were detailed in our previous study²¹. Briefly, the *QPLEX*TM kit utilized Quantamatrix's multiplex diagnostics platform (QMAP; Quantamatrix Inc., Seoul, Republic of Korea)²⁹. First, human plasma samples (singular) were diluted in diluent buffer and incubated with the coded beads and biotin-conjugated detection antibodies (angiotensin-converting enzyme, ACE, DY929, R&D Systems, Minneapolis, USA; galectin-3 binding protein, LGALS3BP, DY2226, R&D Systems; periostin, POSTN, DY3548B, R&D Systems; A β 1–40, 014-26923, Wako, Japan). The immuno-complexes were washed twice with washing buffer at a Biotek-510 magnetic wash station (Biotek, VT, USA). Diluted R-phycoerythrin-conjugated streptavidin was added to each well. After three washes, the immunocomplexes were resuspended in 100 μl of washing buffer by tapping and automatically analyzed using the QMAPTM system. The intra/interassay coefficients of variation and limits of detection were as follows: ACE, intra: 4.9%, inter: 5.1%, 0.22 ng/ml; LGALS3BP, intra: 1.1%, inter: 5.7%, 0.04 ng/ml; POSTN, intra: 9.0%, inter: 6.0%, 0.034 ng/ml; and A β 1–40, intra: 5.3%, inter: 3.9%, 0.50 pM.

Monotone regression spline analysis

Analyses for monotone penalized regression splines were performed to identify the relationship between each biomarker response and imaging biomarkers³⁰. Monotone curves were generated using the smoothing spline method with four knots. To effectively compare different *QPLEX*TM biomarkers, their levels were transformed to z scores. The participants' age acted as a proxy for the progression time.

Statistical analyses

GraphPad Prism 8 (San Diego, CA, USA) and MedCalc version 20.009 software (Ostend, Belgium) were used for all statistical analyses. Comparison analyses between two variables were conducted by independent *t* tests or analyses of covariance (ANCOVAs) with correction for age and sex. Spearman correlation analysis or partial correlation analysis (with the correction of covariates) was performed as appropriate. Logistic regression analysis followed by receiver operating characteristic (ROC) curve analysis was conducted to determine the discriminatory power, sensitivity, and specificity for each of the biomarker panels. The formulas, coefficients, and constants could be optimized since there were appropriate outliers and various logistic regression models. By using the values of variance inflation factors, multicollinearities were checked. All statistical outliers (two samples for A β 1–40, three samples for POSTN, four samples for ACE, and no outliers for LGALS3BP) were excluded from the cohort in accordance with Grubb's double-sided outlier test ($p < 0.05$).

RESULTS

Experimental design and categorization of participants

The overall experimental design of the study is shown in Fig. 1a, b. We previously reported that our *QPLEX*TM biomarkers (A β 1–40, POSTN, LGALS3BP, and ACE) showed significant differences between age-matched (age >55 years old) PiB[−] and PiB⁺ participants (Fig. 1a)²¹. In this study, we utilized biomarkers to determine whether amyloid accumulated within the CN group (CN[−], $n = 185$, PiB-PET negative; CN⁺, $n = 36$, PiB-PET positive; Table 1) (Fig. 1a). Notably, we included participants <55 years of age. However, we needed to first identify the age group that was the most suitable CN group for the application of our *QPLEX*TM Alz plus assay kit (Fig. 1b). We attempted to identify age-dependent changes in our *QPLEX*TM biomarkers and finally concluded that the analyses should be specified for the 3rd tertile age group (>65 years) for the accurate application of our kit (Fig. 2a–f). The demographic data based on age (1st–3rd tertile) are shown in Supplementary Table 1. Next, we performed partial correlation analyses to identify the correlations between our *QPLEX*TM




Fig. 1 Experimental design. **a** Classification of participants and different brain areas from our previous study. The current study focused on the CN group (including CN⁻ individuals <55 years old), whereas our previous study covered all age-matched cognitive groups with individuals >55 years old. **b** Overall experimental design. The experimental processes were as follows: age-dependent characterization of QPLEX™ biomarkers, partial correlation analysis between the biomarkers and cerebral amyloid deposition in specific age groups, testing for the discrimination powers of our QPLEX™ biomarkers in the specific age group, and maximization of biomarker efficiency for CN⁻ vs. CN⁺ with an additional variable.

biomarkers and cerebral amyloid deposition in different brain regions (four ROIs) (Fig. 3a-d). ROC curve analysis followed by logistic regression analysis was successively performed to identify the discrimination powers of our QPLEX™ biomarkers in the 3rd tertile (>65 years) group (Figs. 4a-d and 5a-c). Finally, we attempted to maximize the efficiency of our biomarkers by combining the QPLEX™ biomarkers and plasma Aβ 1–42 (Fig. 5d, e). We achieved an area under the curve (AUC) of 0.921 with 95.7% sensitivity and 67.3% specificity. The experiments and analyses shown in Fig. 1b are described in greater detail below.

Age-dependent characterization of QPLEX™ biomarkers without any effects of AD pathology

First, we tested the effects of age and sex, which are generally known as confounders of AD, on our biomarkers (Fig. 2a-c). Notably, we only used CN⁻ samples for Fig. 2a-c to exclude the effects of AD pathology on the results of testing the

confounders (age and sex). Interestingly, our monotone regression spline analysis revealed three different curve patterns of biomarkers based on age (Fig. 2a). The cutoff dividing lines (42 and 65 years old) separating age groups were determined by the vertices of each biomarker curve (POSTN and ACE showed the first vertex at 42 years old; POSTN, ACE, and LGALS3BP showed the second vertex at 65 years old; Aβ1–40 showed unclear vertices). Based on this cutoff criterion, we defined three age groups as the 1st, 2nd, and 3rd tertiles. Interestingly, the second cutoff point (65 years old) exactly matched the standard age for late-onset AD (Fig. 2a)³¹. Next, we identified no differences in biomarkers between males and females (Fig. 2c). Furthermore, all of the biomarkers showed significant correlations between them (Fig. 2b) but with low values of the variance inflation factors (<2), which indicated that they could suitably be used as variables for logistic regression. Thus, based on these results, we concluded that biomarker analyses should

Table 1. Demographic data of the participants ($n = 221$).

Characteristics (n)	CN ⁻ (185)	CN ⁺ (36)	P value
Sex, M/F	80/105	20/16	0.1755 ^b
Age, years, mean \pm SEM	55.89 \pm 1.2	74.47 \pm 1.0	<0.0001 ^a
Education, mean \pm SEM	12.82 \pm 0.3	12.08 \pm 0.8	0.3846
MMSE raw score, mean \pm SEM	27.78 \pm 0.2	27.17 \pm 0.4	0.1346
MMSE z score, mean \pm SEM	0.48 \pm 0.1	0.44 \pm 0.1	0.7873
CDR (n)	0 (185)	0 (36)	–
ApoE4 positivity, $\epsilon 4 + / N$ (%)	40/185 (22%)	12/36 (33%)	0.1305 ^b
PIB (SUVR), mean \pm SEM	1.09 \pm 0.004	1.62 \pm 0.05	<0.0001 ^a

CN Cognitively normal, *PIB* Pittsburgh compound B, – or + *PIB* positivity, SEM standard error of the mean, n number of participants, MMSE Mini-Mental State Examination, MMSE z score revised value of the MMSE score with consideration for age, sex, and education level, CDR Clinical Dementia Rating, ApoE Apolipoprotein E, SUVR Standardized uptake value ratio, N total number of participants.

^asignificance by t test.

^bsignificance by chi-square test.

be specified for the 3rd tertile age group (>65 years) for a more accurate application of our kit.

Age-dependent approaches for identifying the correlation between QPLEXTM biomarkers and cerebral amyloid deposition

Since the QPLEXTM biomarkers showed different patterns among the age groups, we investigated the relationships between the biomarkers and cerebral amyloid deposition (SUVR) in each age group (1st tertile–3rd tertile) (Fig. 2d–f). The correlations between cerebral amyloid deposition and the QPLEXTM biomarkers were not significant in the 1st and 2nd tertile groups. In the 3rd tertile group, we confirmed that POSTN and LGALS3BP levels in blood were significantly correlated with cerebral amyloid deposition (Fig. 2f). Thus, we reconfirmed the need to focus on the 3rd tertile group and further investigated whether the QPLEXTM biomarkers could be utilized to discriminate PiB-PET positivity within this group. Moreover, the 1st and 2nd tertile groups were not appropriate for this analysis because they had too few PiB⁺ participants (Supplementary Table 1). We performed ANCOVA and partial correlation analysis once again for all ages with the correction for covariates (age and sex) to compensate for the age-dependent differences in biomarker levels (Supplementary Fig. 1a–d and Supplementary Table 2) and obtained significant results. However, since the ratio between CN⁻ and CN⁺ was relatively asymmetric (CN⁻, 185; CN⁺, 36; Table 1), we did not perform ROC curve analyses for all age groups.

Relationship between the QPLEXTM biomarkers and cerebral amyloid deposition in the 3rd tertile group (>65 years)

Since our current criteria for PiB-PET positivity were based on the four ROIs in the brain (FR, LP, LT, and PC-PRC), we investigated the detailed correlations between cerebral amyloid deposition (SUVR) and QPLEXTM biomarkers in each of the brain regions (ROIs)²³. We performed a partial correlation analysis in the 3rd tertile group and revealed that each biomarker showed a similar tendency across all brain regions (Fig. 3a–d). As expected, LGALS3BP and POSTN had higher correlations than ACE or A β 1–40. Interestingly, the PC-PRC ROI showed the highest associations with QPLEXTM biomarkers, including A β 1–40 (Fig. 3d). Although there were no obvious differences between the brain ROIs (in terms of correlations),

we decided to maintain our current criteria (at least 1 out of 4 SUVR \geq 1.4, positive, CN⁺; all SUVR < 1.4, negative, CN⁻). Our participants were all CN individuals, and there have been many reports that more conservative thresholds are needed to detect preclinical AD among CN individuals³². We believed that if we used only the global (SUVR \geq 1.4) criteria for PiB-PET positivity, we might have missed some patients in whom AD progression had already commenced.

Next, we performed a comparative analysis between CN⁻ and CN⁺ individuals in the 3rd tertile group. Although the biomarkers did not show any differences between the sexes (Fig. 2c), we included this variable as a covariate because it is a well-known confounder of AD diagnosis³³. Interestingly, two biomarkers, POSTN and LGALS3BP, showed significant differences between CN⁻ and CN⁺ individuals (Fig. 4a–d, left). The overall level of POSTN in blood was significantly higher in individuals with cerebral amyloid deposition above the threshold, whereas LGALS3BP showed the opposite tendency. The partial correlation analysis corrected for age and sex also revealed a significant association between blood biomarker levels and cerebral amyloid deposition (Fig. 4a–d, right). POSTN was positively correlated with cerebral amyloid deposition (partial correlation coefficient $R = 0.2186$, $P = 0.0333$), whereas LGALS3BP was negatively correlated with cerebral amyloid deposition (partial correlation coefficient $R = -0.2626$, $P = 0.0094$). When all the age groups were combined, all the QPLEXTM biomarkers except for ACE showed significant correlations, as shown in Supplementary Fig. 1a–d. Furthermore, the ANCOVA results showed that all CN⁺ groups had significantly different levels of A β 1–40, POSTN, and LGALS3BP than all CN⁻ groups (Supplementary Table 2).

Discriminative ability of the QPLEXTM Alz plus assay for CN⁻ vs. CN⁺ in the 3rd tertile group (>65 years)

Although A β 1–40 and ACE did not show significant results similar to the previous analyses (Figs. 3a–d and 4a–d; Supplementary Table 3), we decided to include A β 1–40 and ACE in our biomarker panel because a multiple regression analysis including all CN groups (the dependent variable ‘cerebral amyloid deposition’ was included as one of the continuous variables) revealed that all the QPLEXTM biomarkers, including A β 1–40 and ACE, showed a significant correlation with cerebral amyloid deposition (SUVR) in every combination of variables (Table 2). We believe that these results indicate the possibility of potential associations for the logistic model with cerebral amyloid deposition. We performed logistic regression and ROC curve analysis to identify the discriminative ability of our QPLEXTM Alz plus assay in the 3rd tertile group (Fig. 5a). When the three ROC curves were compared with each other, we found that adding QPLEXTM biomarkers dramatically increased the AUC (0.622 to 0.878, curve I vs. curve III; 0.684 to 0.878, curve II vs. curve III) (Fig. 5b). Each graph revealed high sensitivity and specificity (curve I, 82.4% sensitivity and 42.9% specificity; curve II, 52.9% sensitivity and 82.5% specificity; curve III, 69.7% sensitivity and 98.4% specificity) (Fig. 5c).

Maximization of the discrimination power for CN⁻ vs. CN⁺ by adding plasma A β 1–42 as a variable in the 3rd tertile group

Since our QPLEXTM Alz plus assay kit did not include plasma A β 1–42, we conducted a further logistic regression analysis to maximize our discrimination power for CN⁻ vs. CN⁺ in the 3rd tertile group (Fig. 5d–e). Due to limited resources, we only performed a bioplex assay using plasma samples from 75 participants of the 97 participants in the 3rd tertile group. Since this assay is also a multiplex platform, we could obtain both plasma A β 1–42 and A β 1–40 values. Although the plasma A β 1–42/1–40 ratio is a suitable biomarker for AD, our QPLEXTM Alz plus assay kit showed a significantly higher AUC value (0.909) than that of the plasma A β 1–42/1–40 ratio (Fig. 5e). Moreover, when we combined these variables (four QPLEXTM biomarkers + plasma




Fig. 2 Age-dependent characterization of QPLEX™ biomarkers in cognitively normal (CN) participants (2a-2c, CN⁻ only; 2d-2f, entire CN group). **a** A monotone spline model for QPLEX™ biomarkers. The ages of the participants acted as a proxy for time. The levels of QPLEX™ biomarkers were transformed to z scores. The patterns of each biomarker revealed differences based on age groups (the 1st tertile, ≤42 years; 2nd tertile, 42–65 years; 3rd tertile, >65 years). The curves were created by a smoothing spline with four knots. **b** Pearson's correlation between the QPLEX™ biomarkers. Colored and white boxes show R and P values, respectively. We confirmed that all the variables had low values of variance inflation factors (VIF < 2). **c** No significant differences in QPLEX™ biomarkers between males and females. P values were obtained from a two-sided unpaired t test. **d-f** Correlation between the QPLEX™ biomarkers and cerebral amyloid deposition (SUVR) based on age group (**d**, 1st tertile; **e**, 2nd tertile; **f**, 3rd tertile). The levels of QPLEX™ biomarkers were transformed to z scores. Only the 3rd tertile group showed significant results. P values were obtained from Spearman correlation analysis (cutoff, *p < 0.05, and **p < 0.01). Abbreviations: Aβ1-40 beta-amyloid 1-40, POSTN periostin, LGALS3BP (LGAL) galectin-3 binding protein, ACE angiotensin-converting enzyme, SUVR standardized uptake value ratio.

Aβ1-42; plasma Aβ1-40 from the bioplex assay could not be used as a variable due to statistical redundancy) to maximize the discrimination power for CN⁻ vs. CN⁺, the AUC reached 0.921 with 95.7% sensitivity and 67.3% specificity. These results likely suggest that our QPLEX™ Alz plus assay can be used for prescreening amyloid deposition in the brain even when there are no apparent symptoms of cognitive disorders. Given these findings, the future development of the 2nd generation of our kit with plasma Aβ1-42 is highly encouraged.

DISCUSSION

Similar to the treatment of most diseases, including cancer and cardiac disease, AD has a better chance of being treated optimally before the severe progression of cognitive impairment, and the optimal strategy involves early diagnosis during the initial stage of AD pathogenesis³⁴. Preclinical AD is a disease stage that initiates brain pathology and silent symptoms³⁴. The identification of preclinical AD can be performed by assessing cerebrospinal fluid

Aβ, tau, and p-tau using functional PET and MR imaging³⁵. However, these modern imaging techniques are difficult to access due to their high cost and invasiveness^{36,37}. Easily accessible and efficient blood-based biomarkers for diagnosis are necessary for the early detection and prevention of disease progression.

Previously, we identified blood biomarkers that can differentiate those with from those without cerebral amyloid deposition and suggested the possible relevance of these biomarkers in AD diagnosis¹¹. Based on these blood biomarkers, the QPLEX™ Alz plus assay kit was developed, and the efficiency of its diagnostic performance was assessed by clinically applying it to a large population cohort >55 years of age involving CN, MCI, and AD groups²¹. In the present study, we focused on QPLEX™ biomarkers in CN individuals across a broad age range, including CN individuals <55 years of age.

First, we performed a monotone regression spline analysis using CN individuals, including those <55 years old, in which the participants' age acted as a proxy for time (Fig. 2a). Previous studies have suggested that the levels of several blood biomarkers




Fig. 3 Correlations between the *QPLEX*TM biomarkers and cerebral amyloid deposition in various brain ROIs in the 3rd tertile group (>65 years). **a–d** Partial correlation analysis between *QPLEX*TM biomarkers and cerebral amyloid deposition (SUVR) from four ROIs in the 3rd tertile group (>65 years) with correction for age and sex. *P* value cutoff, #*p* < 0.10, **p* < 0.05, and ***p* < 0.01. *P* partial correlation *P* value, *R* partial correlation coefficient. Dotted lines indicate 95% confidence intervals. Abbreviations: ROI region of interest, CN cognitively normal, - or + PIB positivity, Aβ1–40 beta-amyloid 1–40, POSTN periostin, LGALS3BP galectin-3 binding protein, ACE angiotensin-converting enzyme.

show different patterns based on age or sex in healthy individuals³⁸. From this monotone regression spline analysis, we observed a general trend of changes in each *QPLEX*TM blood biomarker based on age in the absence of AD pathology. With the CN status of participants confirmed based on the PiB-PET and Clinical Dementia Rating, we indirectly observed the manner in which our biomarkers underwent overall systemic changes under normal physiological conditions. Interestingly, the vertices of the monotone regression spline curve segmented the population into three age groups with distinct trends in the *QPLEX*TM biomarkers. Further correlation analyses focusing on individual age groups revealed a significant correlation between cerebral amyloid deposition and biomarker levels in the 3rd tertile group (Fig. 2f). These results, coupled with the fact that 65 years is a clinical standard in sporadic AD and individuals in this age group are the most vulnerable to dementia, led us to focus mainly on the 3rd tertile group. Since the monotone spline curve in Fig. 2a was based on the ‘no cerebral amyloid deposition group’, the fluctuations in the curve were relatively minor compared to the range of change related to the progression of AD pathology. The aim of the monotone spline curve was to narrow down the subject of interest to the 3rd tertile group, which showed a

consistent trend that was aligned with their age. The stable features in the 3rd tertile group were suitable for our biomarker analysis and needed to be specifically analyzed.

The abnormal atrophy and accumulation pattern of cerebral amyloid that occurs in specific brain regions is tightly associated with AD progression and can be utilized for diagnosis^{39,40}. To investigate the correlation between biomarkers and pathology in detail, we performed a partial correlation analysis between each *QPLEX*TM biomarker level and amyloid deposition in four different brain regions: PC-PRC, LP, FR, LT (Fig. 3a–d). Interestingly, LGALS3BP showed the most significant correlation, followed in descending order by POSTN, Aβ1–40, and ACE (Fig. 3a–d). This finding was fairly consistent with the results from a previous report that included CN, MCI, and AD groups²¹. The prior results from Park et al. and the results in Fig. 4a–d in this study demonstrate the most significant association of LGALS3BP, followed by POSTN with cerebral amyloid deposition in overall SUVR, suggesting that LGALS3BP and POSTN are valid blood biomarkers in various stages of disease progression. Aβ1–40 was most closely associated with the PC-PRC among the brain regions, which might be due to stage-specific vulnerability of the PC-PRC during AD pathogenesis. The PC-PRC is involved in




Fig. 4 *QPLEX*TM biomarkers and cerebral amyloid deposition in the 3rd tertile group (>65 years). **a–d** Each graph on the left shows the comparison of *QPLEX*TM biomarker levels between CN⁻ individuals and CN⁺ individuals within the 3rd tertile group. A two-sided unpaired *t* test was performed. Each graph on the right shows the results of a partial correlation analysis with correction for age and sex. *P* value cutoff, **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001. *P* partial correlation *P* value, *R* partial correlation coefficient. Dotted lines indicate 95% confidence intervals. Abbreviations: CN cognitively normal; – or + PiB positivity, Aβ1–40 beta-amyloid 1–40, POSTN periostin, LGALS3BP galectin-3 binding protein, ACE angiotensin-converting enzyme.

the early stage of AD development^{41–43} and acts as one of the earliest regions of amyloid accumulation^{40,44–47}. It has been implicated in beta-amyloid-related hypermetabolism in the early disease stage, showing abnormally increased amyloid accumulation⁴⁸. From this point of view, we can speculate that the level of brain amyloid in the PC-PRC is better represented in the plasma because it is the predominant brain region that accumulates amyloid at the earliest stage. The PC-PRC also showed the greatest significance for LGALS3BP and the second greatest for POSTN (Fig. 3a–d), affirming that the region is implicated in early brain amyloid accumulation.

Multiple previous reports have demonstrated that plasma Aβ1–42 and tau levels are efficient biomarkers for cerebral amyloid deposition^{12,49–51}. Moreover, the analysis of plasma Aβ42/40 ratios has identified cerebral amyloid deposition not only in prodromal AD but also in preclinical AD^{52,53}. Thus, we performed an additional quantification of plasma Aβ1–42 levels and compared the diagnostic power among the plasma Aβ42/40 ratio, *QPLEX*TM biomarkers, and *QPLEX*TM biomarkers combined with the plasma Aβ42/40 ratio (Fig. 5d, e). The *QPLEX*TM Alz plus assay kit showed a significantly higher AUC value than the plasma Aβ42/40 ratio, and the highest AUC value was observed with *QPLEX*TM combined with plasma Aβ 1–42 (AUC: 0.921). Due to limited resources, different numbers of individuals were included in the ROC analyses that included Aβ1–42, that is, Fig. 5d, e, compared to the analysis in Fig. 5a–c. Although it was not possible to directly compare the ROC results between Fig. 5a–c and Fig. 5d, e due to the difference in numbers, when we compared the AUC values with the similar range of the

sensitivity (81–82%) between the two models, the inclusion of Aβ1–42 with *QPLEX*TM increased the efficiency of the diagnosis compared to *QPLEX*TM alone from 0.878 (81.82% sensitivity, 67.21% specificity) to 0.921 (82.61% sensitivity, 78.85% specificity). This result proves the efficiency of the *QPLEX*TM Alz plus assay kit, as well as the synergistic effect of the combinational use of *QPLEX*TM Alz plus assay kit with well-known biomarkers such as plasma Aβ 1–42.

In this study, Aβ1–42 was quantified with xMAP, which is considered a highly available and cost-effective method. Recently developed detection methods, such as SIMOA, can offer a lower detection limit by reducing fluorescence signal diffusion, and IP-MS is beneficial in that trace amounts of plasma Aβ can first be enriched by immunoprecipitation and then subsequently analyzed with mass spectrometry. However, this fastidious procedure is difficult to perform in the clinic or hospital for diagnostic purposes. The difficulty in quantifying plasma Aβ1–42 levels due to aggregation tendency and low concentration in blood makes it difficult to include this biomarker in the diagnostic kit, which is a limitation of our study. We look forward to incorporating this biomarker into the panel in the near future, as its inclusion showed higher performance.

Many assays for AD blood biomarkers have been validated to date. Fragments of beta-amyloid or the ratio between isoforms are extensively being investigated⁵⁴. Using IP-MS, Aβ1–42 itself or ratios such as APP669–711/Aβ1–42 and Aβ1–40/Aβ1–42 can be used to discriminate patients with AD from controls⁵⁵. Peripheral tau protein phosphorylation at particular sites indicates brain pathology and can be used to track CNS changes in those with




Fig. 5 Receiver operating characteristic (ROC) curve analysis for PiB-PET positivity within the 3rd tertile group (>65 years). **a** ROC curve analysis for cognitively normal individuals grouped according to PiB-PET positivity. **b** Comparison of ROC curves with different combinations of age, sex, APOE genotype, and QPLEXTM biomarkers as variables. P values were obtained from Delong's test ($*p < 0.05$, $**p < 0.01$, and $***p < 0.001$). **c** Interactive dot diagram (upper) and graph of sensitivity, specificity, and their 95% confidence intervals plotted against the criterion values (lower). **d,e** Maximization of the discrimination power for CN⁻ vs. CN⁺. The AUC reached 0.921 with 95.7% sensitivity and 67.3% specificity. P values were obtained from Delong's test ($*p < 0.05$, $**p < 0.01$, and $***p < 0.001$). Abbreviations: PiB-PET Pittsburgh compound B positron emission tomography, APOE apolipoprotein E, AUC area under the curve, SE standard error, CI confidence interval.

AD⁵⁶. p-tau181, which is increased in preclinical AD⁵⁷, is a scalable marker for predicting and monitoring neurodegeneration in an AD-specific manner⁵⁸. Plasma p-tau217 is also useful; some studies have shown that it has higher accuracy than plasma p-tau181 in detecting abnormal CNS tau metabolism^{56,59}. Recently, plasma p-tau231 was validated as it was correlated with CSF p-tau231 and was useful for predicting incipient AD pathology⁶⁰.

Biomarkers in the QPLEXTM panel are advantageous in that these novel biomarkers have not been extensively discussed in the AD context, and they provide hints regarding the underlying mechanisms of preclinical AD. For example, changes in LGALS3BP and POSTN indicate that the peripheral immune response may have already been altered in preclinical AD^{17,19,20}. As AD is a multifactorial disease, different biomarkers reflect different aspects of AD. While canonical plasma markers such as phosphorylated tau and beta-amyloid fragments, including our plasma Aβ1-40, aim to detect direct products from the brain, the

biomarkers in our panel, such as LGALS3BP, ACE, and POSTN, may reflect secondary effects in the periphery that are primarily caused by AD brain pathology. When our biomarkers are used in conjunction with the panel of previously known blood biomarkers, they can help separate and stratify the patients by identifying the disease subtypes^{8,10,61}.

The kit is practical for use in cognitively normal individuals in various ways. Tests using this kit could be included in regular check-ups or routine physical examinations of elderly individuals, especially those over 65 years old, to detect AD pathogenesis in the early stage. On the other hand, this kit could be the first choice for cognitively normal individuals who visit the doctor's office due to concerns of their AD probability based on family history or ApoE genotype. Additionally, the kit can satisfy the needs of cognitively normal individuals who wish to take precautionary measures without costly brain imaging and be used to screen individuals eligible for clinical trials.

Table 2. Multiple regression analysis on cognitively normal individuals.

QPLEX™ markers							
Dependent Y							Cerebral amyloid deposition (SUVR)
Sample size							215
Coefficient of determination R ²							0.1329
R ² -adjusted							0.1163
Multiple correlation coefficient							0.3645
Residual standard deviation							0.2210
Ind. variables	Coefficient	Std. Error	<i>t</i>	<i>P</i>	<i>r</i> _{partial}	<i>r</i> _{semipartial}	VIF
(Constant)	1.1778						
Aβ1–40	0.0009446	0.0003278	2.881	0.0044	0.1950	0.1851	1.131
LGALS3BP	−0.00002973	0.000008228	−3.613	0.0004	−0.2419	0.2322	1.211
ACE	−0.0004304	0.0001824	−2.359	0.0192	−0.1607	0.1516	1.465
POSTN	0.006219	0.001873	3.320	0.0011	0.2233	0.2134	1.587
QPLEX™ markers + Sex + Age							
Dependent Y							Cerebral amyloid deposition (SUVR)
Sample size							215
Coefficient of determination R ²							0.2613
R ² -adjusted							0.2400
Multiple correlation coefficient							0.5112
Residual standard deviation							0.2049
Ind. variables	Coefficient	Std. Error	<i>t</i>	<i>P</i>	<i>r</i> _{partial}	<i>r</i> _{semipartial}	VIF
(Constant)	0.9098						
Aβ1–40	0.0006936	0.0003076	2.255	0.0252	0.1545	0.1344	1.158
LGALS3BP	−0.00002887	0.000007703	−3.747	0.0002	−0.2515	0.2233	1.234
ACE	−0.0003556	0.0001698	−2.094	0.0375	−0.1437	0.1248	1.476
POSTN	0.006376	0.001738	3.669	0.0003	0.2465	0.2186	1.588
Sex	−0.02188	0.02842	−0.770	0.4421	−0.0533	0.0459	1.024
Age	0.005013	0.0008386	5.977	<0.0001	0.3829	0.3562	1.026
QPLEX™ markers + Sex + Age + ApoE genotype							
Dependent Y							Cerebral amyloid deposition (SUVR)
Sample size							215
Coefficient of determination R ²							0.2810
R ² -adjusted							0.2567
Multiple correlation coefficient							0.5301
Residual standard deviation							0.2027
Ind. variables	Coefficient	Std. Error	<i>t</i>	<i>P</i>	<i>r</i> _{partial}	<i>r</i> _{semipartial}	VIF
(Constant)	0.8908						
Aβ1–40	0.0006864	0.0003043	2.256	0.0251	0.1549	0.1329	1.158
LGALS3BP	−0.00002854	0.000007619	−3.746	0.0002	−0.2519	0.2207	1.234
ACE	−0.0003705	0.0001680	−2.205	0.0286	−0.1515	0.1299	1.478
POSTN	0.006314	0.001719	3.674	0.0003	0.2474	0.2165	1.589
Sex	−0.01911	0.02813	−0.679	0.4977	−0.0472	0.0400	1.025
Age	0.005049	0.0008295	6.087	<0.0001	0.3896	0.3587	1.027
ApoE	0.07754	0.03259	2.379	0.0183	0.1632	0.1402	1.006

SUVR standardized uptake value ratio, *Ind.* independent, *VIF* variance inflation factor, *Aβ1–40* beta-amyloid 1–40, *LGALS3BP* galectin-3 binding protein, *ACE* angiotensin-converting enzyme, *POSTN* periostin, *ApoE* apolipoprotein E.

REFERENCES

1. Collaborators, G. B. D. D. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **18**, 88–106 (2019).
2. Baik, S. H. et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer's disease. *Cell Metab.* **30**, 493–507 e496 (2019).
3. Choi, H. et al. Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models. *Aging Cell* **19**, e13081 (2020).

4. Cha, M. Y. et al. Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. *Hum. Mol. Genet.* **24**, 6492–6504 (2015).
5. Murphy, M. P. & LeVine, H. 3rd Alzheimer's disease and the amyloid-beta peptide. *J. Alzheimers Dis.* **19**, 311–323 (2010).
6. Uzuegbunam, B. C., Librizzi, D. & Hooshyar Yousefi, B. PET. Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. *Molecules* **25**, 977 (2020).
7. Burnham, S. C. et al. A blood-based predictor for neocortical A β burden in Alzheimer's disease: results from the AIBL study. *Mol. Psychiatry* **19**, 519–526 (2014).
8. Hampel, H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat. Rev. Neurol.* **14**, 639–652 (2018).
9. Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol.* **9**, 119–128 (2010).
10. Zetterberg, H. & Burnham, S. C. Blood-based molecular biomarkers for Alzheimer's disease. *Mol. Brain* **12**, 26 (2019).
11. Park, J. C. et al. Prognostic plasma protein panel for A β deposition in the brain in Alzheimer's disease. *Prog. Neurobiol.* **183**, 101690 (2019).
12. Park, J. C. et al. Chemically treated plasma A β is a potential blood-based biomarker for screening cerebral amyloid deposition. *Alzheimers Res. Ther.* **9**, 20 (2017).
13. Risacher, S. L. et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. *Alzheimers Dement. (Amst.)* **11**, 510–519 (2019).
14. Hemming, M. L. & Selkoe, D. J. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. *J. Biol. Chem.* **280**, 37644–37650 (2005).
15. Hu, J., Igarashi, A., Kamata, M. & Nakagawa, H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A β); retards A β aggregation, deposition, fibril formation; and inhibits cytotoxicity. *J. Biol. Chem.* **276**, 47863–47868 (2001).
16. Zou, K. et al. Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (A β (1–42)) to A β (1–40), and its inhibition enhances brain A β deposition. *J. Neurosci.* **27**, 8628–8635 (2007).
17. Liu, A. Y., Zheng, H. & Ouyang, G. Periostin, a multifunctional extracellular matrix protein in inflammatory and tumor microenvironments. *Matrix Biol.* **37**, 150–156 (2014).
18. Mathys, H. et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. *Cell Rep.* **21**, 366–380 (2017).
19. Laubli, H. et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. *J. Biol. Chem.* **289**, 33481–33491 (2014).
20. Ullrich, A. et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. *J. Biol. Chem.* **269**, 18401–18407 (1994).
21. Park, J. C. et al. Performance of the QPLEX Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition. *Alzheimers Res. Ther.* **13**, 12 (2021).
22. Byun, M. S. et al. Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics. *Psychiatry Investig.* **14**, 851–863 (2017).
23. Reiman, E. M. et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc. Natl Acad. Sci. USA* **106**, 6820–6825 (2009).
24. Jack, C. R. Jr. et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. *Lancet Neurol.* **13**, 997–1005 (2014).
25. Jack, C. R. Jr. et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. *Neurology* **82**, 1605–1612 (2014).
26. Jack, C. R. Jr. et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. *Neurology* **81**, 1732–1740 (2013).
27. Vemuri, P. et al. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. *Alzheimers Dement. (Amst.)* **6**, 21–30 (2017).
28. Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. *Brain* **138**, 1370–1381 (2015).
29. Chung, S. E. et al. Optofluidic maskless lithography system for real-time synthesis of photopolymerized microstructures in microfluidic channels. *Appl. Phys. Lett.* **91**, 041106 (2007).
30. Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol. Med.* **11**, e11170 (2019).
31. Isik, A. T. Late onset Alzheimer's disease in older people. *Clin. Interv. Aging* **5**, 307–311 (2010).
32. Ismail, R. et al. Abnormal amyloid load in mild cognitive impairment: the effect of reducing the PiB-PET threshold. *J. Neuroimaging* **29**, 499–505 (2019).
33. Podcasy, J. L. & Epperson, C. N. Considering sex and gender in Alzheimer disease and other dementias. *Dialogues Clin. Neurosci.* **18**, 437–446 (2016).
34. Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 280–292 (2011).
35. Sperling, R. A., Karlawish, J. & Johnson, K. A. Preclinical Alzheimer disease—the challenges ahead. *Nat. Rev. Neurol.* **9**, 54–58 (2013).
36. Wittenberg, R., Knapp, M., Karagiannidou, M., Dickson, J. & Schott, J. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. *Alzheimers Dement. (NY)* **5**, 382–387 (2019).
37. Zhang, S. et al. (11)C-PiB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst. Rev.* **7**, CD010386 (2014).
38. Sebastiani, P. et al. Age and sex distributions of age-related biomarker values in healthy older adults from the long life family study. *J. Am. Geriatr. Soc.* **64**, e189–e194 (2016).
39. Frenzel, S. et al. A biomarker for Alzheimer's disease based on patterns of regional brain atrophy. *Front. Psychiatry* **10**, 953 (2019).
40. Palmqvist, S. et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nat. Commun.* **8**, 1214 (2017).
41. Yokoi, T. et al. Involvement of the precuneus/posterior cingulate cortex is significant for the development of Alzheimer's Disease: A PET (THK5351, PiB) and Resting fMRI Study. *Front. Aging Neurosci.* **10**, 304 (2018).
42. Pengas, G., Hodges, J. R., Watson, P. & Nestor, P. J. Focal posterior cingulate atrophy in incipient Alzheimer's disease. *Neurobiol. Aging* **31**, 25–33 (2010).
43. Maarouf, C. L. et al. Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease. *PLoS One* **9**, e105784 (2014).
44. Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O. Staging beta-Amyloid Pathology With Amyloid Positron Emission Tomography. *JAMA Neurol.* **76**, 1319–1329 (2019).
45. Villemagne, V. L. et al. Longitudinal assessment of A β and cognition in aging and Alzheimer disease. *Ann. Neurol.* **69**, 181–192 (2011).
46. Villain, N. et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. *Brain* **135**, 2126–2139 (2012).
47. Insel, P. S., Mormino, E. C., Aisen, P. S., Thompson, W. K. & Donohue, M. C. Neuroanatomical spread of amyloid beta and tau in Alzheimer's disease: implications for primary prevention. *Brain Commun.* **2**, fcaa007 (2020).
48. Oh, H., Madison, C., Baker, S., Rabinovici, G. & Jagust, W. Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. *Brain* **139**, 2275–2289 (2016).
49. Fandos, N. et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. *Alzheimers Dement. (Amst.)* **8**, 179–187 (2017).
50. Park, J. C. et al. Plasma tau/amyloid-beta1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *Brain* **142**, 771–786 (2019).
51. Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol.* **19**, 422–433 (2020).
52. Perez-Grijalba, V. et al. Plasma A β 42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. *Alzheimers Res. Ther.* **11**, 96 (2019).
53. Doecke, J. D. et al. Total A β 42/A β 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. *Neurology* **94**, e1580–e1591 (2020).
54. Kaneko, N., Yamamoto, R., Sato, T. A. & Tanaka, K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **90**, 104–117 (2014).
55. Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. *Nature* **554**, 249–254 (2018).
56. Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. *J. Exp. Med.* **217**, e20200861 (2020).
57. Janelidze, S. et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat. Med.* **26**, 379–386 (2020).
58. Moscoso, A. et al. Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. *JAMA Neurol.* **78**, 396–406 (2021).
59. Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. *JAMA* **324**, 772–781 (2020).
60. Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol.* **141**, 709–724 (2021).
61. Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. *Nat. Med.* **13**, 1359–1362 (2007).

ACKNOWLEDGEMENTS

This work was supported by grants from the National Research Foundation of Korea (NRF2019R111A1A01063525 to S-H. Han) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and funded by the Ministry of Health & Welfare, Republic of Korea (HI19C1132, HU20C0187, & HU20C0198 to I. Mook-Jung), NRF (2018R1A5A2025964 to I. Mook-Jung, 2014M3C7A1046042 to D. Y. Lee), and KHIDI (HI18C0630 & HI19C0149 to D. Y. Lee). We sincerely thank all the patients, hospital staff, and volunteers involved in this project. We also thank Eun-Hye Kim for technical support in purifying and obtaining the plasma samples.

AUTHOR CONTRIBUTIONS

D.L. and J.-C.P. and I.M.-J. conceptualized the study. D.L., J.-C.P., K.S.J., J.K., J.S.J., and S.K. performed the experiments. M.S.B., D.Y., G.B., and G.J. obtained all blood samples from the participants and gathered all the data. After PET scan data were obtained and collected, they were analyzed by Y.K.K., M.S.B., D.Y., and J.-C.P. conducted the statistical analyses. D.L. and J.-C.P. analyzed the statistics and organized all the figures and tables. D.Y.L. provided the resources. D.L., J.-C.P. and S.-H.H. wrote the original draft. S.-H.H., D.Y.L., and I.M.-J. reviewed and edited the manuscript. All authors have carefully read and approved the final manuscript.

ETHICAL APPROVAL

All participants included in this study and (where applicable) their legal representatives carefully read and confirmed the informed consent documents. This study was approved by the Seoul National University Hospital Institutional Review Board (IRB, C-1401-027-547).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s12276-021-00719-3>.

Correspondence and requests for materials should be addressed to Dong Young Lee, Sun-Ho Han or Inhee Mook-Jung.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022